Article continued…
Results
The results of the study are shown in Table 1. Total cholesterol, LDL cholesterol, and triglycerides were significantly reduced. Total cholesterol was reduced in 10 of 13 subjects. Of seven subjects whose total cholesterol level was higher than the normal range at baseline, three subjects showed decreases to within the normal range. LDL cholesterol was reduced in nine subjects. Of six subjects whose LDL cholesterol level was higher than the normal range, four subjects showed decreases to within the normal range.
Fibrinogen was reduced in nine subjects. Of six subjects whose fibrinogen level exceeded the normal range at baseline, four subjects showed decreases to within the normal range after the study period.
Furthermore, HgbA1c, hs-CRP, and body weight significantly decreased. Among the 13 subjects, a decrease in HgbA1c was seen in 10 subjects, in hs-CRP for 10 subjects, and in body weight for 13 subjects, respectively.
Discussion
Total cholesterol, LDL cholesterol, and triglycerides were significantly reduced, suggesting that Plasmanex1 possesses lipid metabolism-improving potentials. A significant decrease in HgbA1c was observed, suggesting its potential in diabetes and pre-diabetes. A significant decrease in hs-CRP was also observed, suggesting its anti-inflammatory potential. Furthermore, body weight was significantly reduced, suggesting its body-weight reduction potential.
This study was a small-scaled, open test, and further research is required. However, this study suggests that Plasmanex1 possesses lipid-metabolism improvement, blood-viscosity reduction, anti-diabetes, anti-inflammatory, and body-weight reduction potentials, and can contribute to improvement of metabolic disorders and metabolic syndrome.
While it is still necessary to be acutely aware of communicable diseases, this modern era is markedly characterized by lifestyle diseases. Lifestyle diseases are defined as diseases linked with the way people live their life. These are non-communicable diseases. This is commonly caused by lack of physical activity, unhealthy eating, alcohol, drugs, and smoking. Diseases that mostly have an effect on our lifestyle are heart disease, stroke, obesity, and type II diabetes.
Plasmanex1 appears to have properties that can contribute to curbing the metabolic biologic markers associated with our current lifestyles. Further research is needed to ascertain who are the best candidates and including a dietary trial along with Plasmanex1 to see if the outcomes are even stronger.
References
- Katagiri R, et al. BMJ. 2020;368:m34 | doi: 10.1136/bmj.m34 (2020)
- Yamashita T, et al. Pathophysiol Haemost Thromb. 2003; 33:138-143.
- Omura K, et al. J Pharmacol Sci. 2005; 99: 247-251.
- Hitosugi M, et al. J Hypertens.2014; 3 :135. doi: 10.4172/2167-1095.1000135
- Hitosugi M, et al. International Journal of General Medicine. 2015; 8: 41–46.
- Sunagawa Y, et al. Biol. Pharm. Bull. 2018; 41[J1] : 504–509.
Fred Pescatore, MD. MPH, CCN, is a Manhattan-based traditionally trained physician and internist who specializes in nutritional medicine. He is a globally renowned health, nutrition, and weight loss expert, as well as the author of seven books, including the New York Times bestsellers The Hamptons Diet and newly released The A-List Diet. He is the president of the International and American Association of Clinical Nutritionists and a member of the College for the Advancement of Medicine. Dr. Pescatore’s extraordinary background in complementary medicine led him to open his globally recognized medical center, Medicine 369, in New York City. The rapidly expanding practice is credited as one of the most effective and successful integrative medical centers worldwide. He has studied in America, Southeast Asia, India, Japan, Africa, and Europe and is sought after as one of the frontline educators and visionaries improving health care and human life.
